ENDOMETRIAL CANCER

This adverse event was reported 2202 times

These drugs are most commonly taken by patients reporting ENDOMETRIAL CANCER:

# Drug Count
0 METHOTREXATE SODIUM 99
1 ADALIMUMAB 97
2 RALOXIFENE HYDROCHLORIDE 94
3 METHOTREXATE 91
4 CONJUGATED ESTROGENS 89
5 ESTROGENS, CONJUGATED 89
6 LEVONORGESTREL 85
7 MEDROXYPROGESTERONE ACETATE 81
8 ERGOCALCIFEROL 80
9 RANITIDINE 79
See all common drugs associated with ENDOMETRIAL CANCER

ENDOMETRIAL CANCER is most prevalent among patients taking these drugs:

# Drug Count Frequency
0 ESTRIOL,ESTRADIOL 1 0.2000
1 CLOTRIMAZOLE1% CLOTRIMAZOLE 1 0.0182
2 TOREMIFENE CITRATE 5 0.0116
3 ESTRADIOL VALERATE 8 0.0103
4 RELACORILANT 1 0.0101
5 DOSTARLIMAB 20 0.0080
6 TAMOXIFEN CITRATE 45 0.0078
7 CONJUGATED ESTROGENS/BAZEDOXIFENE 5 0.0053
8 BROMOCRIPTINE MESYLATE 3 0.0046
9 POLYETHYLENE GLYCOL 3350, SODIUM CHLORIDE, SODIUM BICARBONATE, POTASSIUM CHLORIDE 1 0.0040
See all drugs enriched for association with ENDOMETRIAL CANCER

ENDOMETRIAL CANCER is most prevalent among patients taking these drug classes:

# Drug class Count Frequency
0 Interleukin-5 Antagonist [EPC] 7 0.0102
1 Estrogen Agonist/Antagonist [EPC] 8 0.0031
2 Provitamin D2 Compound [EPC] 80 0.0027
3 Androgen [EPC] 29 0.0011
4 Estrogen [EPC] 181 0.0010
5 Calcitonin [EPC] 3 0.0010
6 Blood Viscosity Reducer [EPC] 4 0.0009
7 Progesterone [EPC] 20 0.0008
8 Progestin Antagonist [EPC] 4 0.0008
9 Interleukin-17A Antagonist [EPC] 30 0.0008
See all drug classes enriched for association with ENDOMETRIAL CANCER